NICE provisional OK for RoActemra in RA Pharma Times In August 2010, NICE issued guidance TA198, which recommends RoActema as an option for people with RA if there has been an inadequate response to one or more tumour necrosis factor (TNF) inhibitors and where Roche's MabThera/Rituxan (rituximab) has ... |
